Try our Advanced Search for more refined results

February 08, 2021

CELGENE CORPORATION v. DR. REDDY'S LABORATORIES, LTD. et al

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. January 31, 2022

    Celgene, Dr. Reddy's Settle Generic Cancer Drug Row

    Bristol-Myers Squibb subsidiary Celgene has settled litigation in the U.S. that sought to block Indian drugmaker Dr. Reddy's from marketing generic versions of its blockbuster cancer medication Pomalyst, according to documents that the two sides filed on Friday in New Jersey federal court.

1 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login